Articles On Hera Med (ASX:HMD)

The ASX200 is trading up just over half a per cent. Most sectors are in the green, Healthcare is leading intraday gains, up around 1.3 per cent, Materials follows, up more than a per cent. The IT sector has dipped the most, down aroun...

Stockhead’s Top 10 at 10, published each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percenta...

HeraMED (ASX:HMD) shares are surging following the announcement of a partnership agreement with Telstra Health The collaboration aims to integrate HeraCARE into MedicalDirector Clinical by Telstra Health Telstra Health currently lacks...

PainChek’s European patent HeraMed signs deal with Telstra AdAlta announced interim Phase 1 results Avita lowers 2023 guidance PainChek’s European patent application accepted PainChek (ASX: PCK) announced that the European Patent Office...

The Week That Was The world looks very different this week after the addition of what Barclays economic team calls ‘a complex cocktail of geopolitical risk, mixed macro data, a nervous oil market,’ and a US Fed finding nice things to say ab...

HeraMED (HMD) taps both sophisticated and professional investors for $2.58 million through a private placement The placement involves the issuance of 36.86 million new shares at seven cents per apiece, a 6.67 per cent discount to the com...

ASX dips 0.56% despite a solid kickstart first thing this morning InfoTech outperforms the market again, leading on +0.21% for the day Heavy Minerals banks a 90% bump on some big time garnet news   For 10 fantastic minutes this morning, l...

After a more promising start, the ASX closed out the day up by 0.25%. InfoTech did well (+0.96%), but Health stocks are still anything but, down another 1.97%. Greentech went soaring, up 223% after rock chip assays showed signs of lithium...

HeraMED’s partner E-Lōvu Health signs first three-year deal CareTeq has also signed a deal with the  National Seniors Australia    Medtech company HeraMED (ASX:HMD) says its strategic partner E-Lōvu Health has signed its first three-year...

S&P/ASX 200 closes up 1% – its best performance in about a week  All sectors bar IT and Utilities had green days, with Discretionary and Utilities outperforming Resources & Energy Group had a +183% stonker of a day on its you-beaut...

Paradigm Bio says drug is effective in osteoarthritic dogs HeraMED signed a deal with Fond, a US-based global SaaS platform The first patient has been dosed in Imugene’s clinical trial   Late stage biotech Paradigm Biopharmaceuticals (ASX...

Heramed surged 10pc after signing up a leading private obstetrics  Ecofibre has received two patent grant notifications in the US   Medical data company focusing on maternity care, HeraMED (ASX:HMD), surged as high as 10% this morning aft...

HeraMED (HMD) signs a new contract with Joondalup Obstetrics and Gynaecology Group (JOGG) in Western Australia to deploy its HeraCARE platform The new contract includes an initial purchase of 120 HeraCARE licences and HeraBEAT devices fo...

HeraMED (HMD) announces Gold Coast Hospital will trial its ‘HeraCARE’ platform as its new standard of care for Women Newborn and Children Services (WNCS) The trial will include up to 90 pregnancies for between six to nine months, assessi...

Medical data and technology company HeraMED (ASX:HMD) has announced that it has signed a memorandum of understanding with the Gold Coast Hospital to trial its HeraCARE platform as a new standard of care for their Women Newborn and C...

HeraMED’s first commercial rollout in the US is progressing well Recce Pharma is set to commence Phase I/II clinical trial   Maternity care medtech company, HeraMED (ASX:HMD), says the first phase of its commercial rollout in the US is pr...

HeraMED (HMD) appoints former Nanosonics (NAN) Senior VP, North America, Keith Koby as its President, North America Mr Koby has more than 30 years of experience within the medical technology and devices market He helped Nanosonics’ te...

Race Oncology received positive feedback from the US FDA HeraMed launches HeraCARE in Victoria Mesoblast announced top line results from Phase 3 trial   US FDA pleased with Race Oncology submission Race Oncology (ASX:RAC) has received pos...

HeraMED (HMD) completes a $4 million private placement to fund early commercialisation initiatives The money was raised via the issue of around 30.77 million new ordinary shares priced at 13 cents each – a 13.3 per cent discount to its las...

Small caps and benchmark down over 1% All sectors retreat on ill-winds blowing in from the states Tinkler is back   The ASX 200 has started a new week with its worst session since early July. While that can be pinned on a shift in US sent...

Pregnancy technology company HeraMED (HMD) enters a trading halt as the company prepares to undertake a capital raise Trading of HMD shares will be paused until Wednesday, August 24, or until the company releases further details HMD’s Hera...

HeraMed signs US deal worth $500k Pregnancy medtech specialist, HeraMed (ASX:HMD), was up over 20% this morning after revealing a supply deal with US-based e-Lōvu Health. The expected revenue to HeraMED from the deal is approximately US$550...

HeraMED (HMD) partners with e-Lōvu Health to supply its HeraCARE remote pregnancy monitoring technology to customers in the United States The companies strike a binding term sheet that will see the HeraMED supply 1000 kits to expectant mot...

ASX is set to open higher on Thursday The US Fed raises key rate by 75bp Fed Chair Powell says the US economy is not in a recession Local shares are set to rise on Thursday and at 8am AEST, the ASX 200 August futures is pointing up by 0.9...

Pregnancy technology company HeraMED (HMD) completes the HeraBEAT clinical trial with Israel’s Sheba Medical Center which achieved “excellent” results A total of 10 patients were recruited in the study and went through an observation telem...

Benchmark down, small caps up Utilities ahead 1% and well, the energy sector is on fire And why early buyer James Gerrish from Market Matters was never bearish on WHC  The ASX Emerging Companies (XEC) index has closed 0.6% higher and the...

HeraMED’s device is effective for telemedicine in monitoring pregnant women Mesoblast issues strong study results OncoSil announces success in Spain Just-released results from a clinical trial undertaken by Israel’s Sheba Medical Center c...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

 Highlights Virtual OB paid pilot of HeraMED in partnership with Pediatrix® Medical Group receives excellent satisfaction from patients and encouraging results HeraBEAT enables pregnant mothers to listen to their baby’s heartbeat anyti...

ASX health stocks (XHJ index) are down .99% today but faring better than the ASX 200 which has fallen sharply at 1.5%. The HeraMED (ASX:HMD) share price rallied 6.9% to 31 cents in early morning trade before settling ~3.45% as the company a...

Digital maternity care company HeraMED (HMD) has hit a “truly significant milestone” with a Perth hospital, The Joondalup Health Campus (JHC) JHC has agreed to use the HeraCARE solutions as its primary standard of care for expected mothers...

The ASX 200 posted a small 0.11 fall on Tuesday, outperformed by the small end of town as the microcap Emerging Companies index rose by 0.66%. There were no clear catalysts as Asian markets struggled for direction after Wall Street was clos...

Medical tech company HeraMED (HMD) raises roughly $2.39 million through a convertible note placement The placement was strongly supported by institutional and sophisticated investors The proceeds will fast-track the commercial roll out of...

It’s been a busy morning for the ASX Healthcare sector, with plenty of positive announcements for investors to digest. But the Health Index (XHJ) is trading down by 0.5% at the time of writing, compared to the broader index which is trading...

It’s been a mixed week for the ASX but it has finished on a high. The ASX 200 closed 0.69% higher than yesterday, closing at 7,362 which marked a 3 week high but is still 3.5% above the all time high reached in mid-August. Travel stocks gai...

Local stocks posted a strong session on Thursday, as the ASX 200 climbed by around 1% while the microcap Emerging Markets index jumped again (+1.9%). Asian markets were buoyant more broadly, following a steady session on Wall Street overnig...

Pregnancy technology company HeraMED (HMD) enters a trading halt while it considers, plans and executes a capital raising The company will remain in the halt until October 18 or when an announcement is made released, whichever occurs firs...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Highlights Biotechnology firm Mesoblast extended its loss on disappointing earnings and dropped 5%. Graphite producer Volt Resources dropped despite successfully raising capital via share placement. Medical data and technology firm He...

Highlights The ASX 200 declined as much as 1% by lunchtime as investors awaited June quarter GDP figures. Australia’s Q2 GDP rose 0.7% in the June quarter. Barring energy, all indices were trading in the red, while healthcare declined...

ShareCafeHidden Gems Webinar Recap – EXL, WOA, OSX & HMD Catch up on the full webinar with presentations from  Elixinol Wellness (ASX: EXL), Wide Open Agriculture (ASX: WOA), Osteopore (ASX: OSX)  & HeraMED (ASX: HMD). Hidden Gems...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Summary Advanced Human Imaging has entered into a binding agreement with Jana Care to bring affordable digitally connected care to everyone. PainChek Infant has obtained the necessary regulatory approvals in multiple International mark...

The HeraMED Ltd (ASX: HMD) share price tanked today, closing 9% lower at 15 cents apiece. This came despite the company signed a pilot deal with Obstetrix Medical, one of the USA’s largest women’s and children’s healthcare providers. HeraM...

While there appeared to be several winners out of Budget 2021, few of them were on the ASX. The ASX 200 fell for the second day in a row losing 0.73 per cent to close at 7,045 points. Meanwhile the ASX Emerging Companies Index fell 0.51 per...

After closing at a record high yesterday the ASX retreated by nearly 1 per cent today. The ASX 200 lost 1.06 per cent to close at 7,097 points. The ASX Emerging Companies Index fared worse closing 2.3 per cent in the red – at 2,060 points....

Google April 2021 and the first things you’ll find isn’t ASX winners but questions about COVID-19. Just another month in the pandemic, right? Well, yes and no. On one hand the vaccine race continues across the world – far slower than we’d l...

Summary With the current emergency, it is anticipated that telehealth or telemedicine could be the future of medicine. COVID-19 pandemic resulted in considerable adoption of telehealth solutions, mainly to avoid physical contact. The...

HeraMED has announced a paid pilot with a leading medical provider for 100 expectant mothers. HeraMED’s (ASX:HMD) HeraCARE platform will be rolled out to 100 expectant mothers at WA’s Joondalup Health Campus as part of a landmark paid pilo...

The ASX fell again today, as risk-on sentiment continued to reign supreme in the markets. The ASX 200 fell 0.29 per cent, a smaller drop then yesterday but one that saw it close below 7,000 – at 6,997. Small caps fell by more, with the ASX...